ERCC1蛋白的表达与晚期食管癌含顺铂方案化疗疗效的临床观察

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (5): 546-551.

ERCC1蛋白的表达与晚期食管癌含顺铂方案化疗疗效的临床观察

张虹^1,2, 顾康生¹

¹安徽医科大学第一附属医院肿瘤科,合肥 230022,安徽;
²歙县人民医院肿瘤科,黄山 245200,安徽

收稿日期:2014-12-01 修回日期:2015-02-27 发布日期:2015-06-11
通讯作者: 顾康生,男,博士,教授,主任医师,研究方向:肿瘤的个体化治疗。Tel: 0551-62923504 E-mail: gks63@tom.com
作者简介:张虹,在读硕士,住院医师,研究方向:食管癌的个体化治疗。Tel: 0559-6530292 E-mail: zhanghong_198507@163.com

Clinical observation of ERCC1 protein expression and cisplatin based chemotherapy on advanced esophageal cancer

ZHANG Hong^1,2, GU Kang-sheng¹

¹ Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China;
² Department of Oncology, People's Hospital of She County, Huangshan 245200, Auhui, China

Received:2014-12-01 Revised:2015-02-27 Published:2015-06-11

摘要/Abstract

摘要： 目的: 探讨晚期食管癌患者癌组织中切除修复交叉互补基因1(ERCC1)蛋白的表达与含顺铂方案联合化疗疗效的相关性。方法: 回顾性检测98例晚期食管癌患者肿瘤组织中ERCC1蛋白的表达,观察患者接受含顺铂方案的联合化疗的疗效,分析ERCC1表达与客观有效率、疾病控制率、无进展生存期、总生存期之间的关系。结果: 98例患者ERCC1表达阳性率为 56.1％(55/98),总疾病控制率为 70.4％(69/98),ERCC1表达阴性组的客观有效率(76.7%)优于表达阳性组(38.2%), 差异有统计学意义(χ²=14.506, P=0.000);ERCC1表达阴性组的疾病控制率(88.4%)优于表达阳性组(56.4%), 差异有统计学意义(χ²=11.867, P=0.001);ERCC1表达阳性和阴性的两组无进展生存期和总生存期变化相近(P＞0.05)。结论: 晚期食管癌病理组织中ERCC1阴性表达患者疗效近期有效率优于ERCC1阳性表达患者。

关键词: 食管肿瘤, 顺铂, 切除修复交叉互补基因1

Abstract: AIM: To investigate the relationship between ERCC1 expression in advanced esophageal cancer and the chemotherapy effect treated with cisplatin.METHODS: 98 pathological specimens of advanced esophageal cancer patients were collected to detect ERCC1 expression. All patients received cisplatin chemotherapy The researchers observe the effect of patients receiving cisplatin-containing combination chemotherapy programs, and analyze the relationships between ERCC1 expression and objective response rate, disease control rate, progression-free survival, overall survival.RESULTS: In all 98 patients, the positive rate of ERCC1 expression was 56.1％(55/98), the overall disease control rate was 70.4％ (69/98), while objective response rate in negative group of ERCC 1 expression (76.7%) was higher than that in positive group (38.2%), which showed statistical difference (χ²=14.506, P=0.000); disease control rate in negative group of ERCC1 expression (88.4%) was higher than that in positive group (56.4%), which showed statistical difference (χ²=11.867, P=0.001). The expression of ERCC1 two groups progression-free survival and overall survival difference between positive and negative have similar changes (P＞0.05).CONCLUSION: The recent efficient of patients with ERCC1 negative expression in esophageal cancer pathological tissue is better than that of positive ERCC1 expression.

Key words: esophageal neoplasms, cisplatin, ERCC1

中图分类号:

R735.1

张虹, 顾康生. ERCC1蛋白的表达与晚期食管癌含顺铂方案化疗疗效的临床观察[J]. 中国临床药理学与治疗学, 2015, 20(5): 546-551.

ZHANG Hong, GU Kang-sheng. Clinical observation of ERCC1 protein expression and cisplatin based chemotherapy on advanced esophageal cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 546-551.

参考文献

[1] Galluzzi L, Senovilla L, Witale I, et al. Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15):1869-1883.
[2] Kelland L. The resurgence of platinum-based cancer chemotherapy[J]. Nat Rev Cancer, 2007, 7(8): 573-584.
[3] Reed E, Dabholkar M, Thornton K, et al. Evidence for oder in the appearance of mRNAs of nuceleotide excision repair genes,in human ovarian cancer tissues[J]. Oncol Rep, 2000, 7(11): 1123-1128.
[4] 许良中, 杨文涛. 免疫组织化学反应结果的判断标准[J]. 中国癌症杂志, 1996, 6(4): 229-231.
[5] 黄镜. 晚期食管癌的药物治疗进展[J]. 中国临床研究, 2010, 23(1): 1-4.
[6] Enrica R, Francesco C, Elisa B, et al. ERCC1 C092A (rs3212986) Polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy[J]. Pharmacogenetics Genomics, 2013, 23(11): 597-604.
[7] 魏玲, 李苏宜. 铂类药物治疗食管癌的临床研究进展[J]. 中国肿瘤临床, 2010, 37(4): 238-240.
[8] 蔡瑞刚, 黄镜, 吕纪马, 等. 含顺铂与不含顺铂方案治疗晚期食管癌的临床分析[J]. 中华肿瘤防治杂志, 2008, 15(23): 1818-1820.
[9] Ahaha R, Liang X, Yu JJ, et al. Excision repair cross complementing-group 1: gene expression and platinum resistance[J]. Int J Mol Med, 2004, 14(6): 959-970.
[10]郗照勇, 刘扬中. 顺铂耐药的分子机制[J]. 中国科学:化学, 2014, 44(4): 410-422.
[11]张萌, 刘巍, 王淑琴. ERCC1基因在食管癌中的研究进展[J]. 中国肿瘤, 2009, 18(3): 218-221.
[12]伍青, 朱彦君. 食管癌疗效相关肿瘤生物标志物的研究进展[J]. 中国肿瘤, 2012, 21(10): 775-778.
[13]Olaussen KA. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select nsclc patients for the treatment of cetuximab in combination with cispaltin[J]. Cancer Biol Ther, 2009, 8(20): 1922-1923.
[14]金艺凤, 何贝, 刘东华, 等. 顺铂对人肺腺癌细胞作用与ERCC1、Bcl-2表达的相关性研究[J].中国临床药理学与治疗学, 2013, 18(7): 764-768.
[15]Darren T, Rihong Z, Wei Z, et al. Polymorphisms of the NER pathway genes,ERCC1 and XPD are associated with esophageal adenocarcinoma risk [J]. Cancer Causes Control, 2008, 19(10): 1077-1083.
[16]Joshi MB, Shirota Y, Dancerberg KD, et al. High gene expression of TSI, GSTP1 and ERCC1 are risk facors for survival in patients treated with trimodality therapy for esophageal cancer[J]. Clin Cancer Res, 2005, 11(6): 2215-2221.
[17]Huang J, Zhang H, Qu T, et al. A phase ll study of biweekly palitaxel and cisplatin chemotherapy for recurrent or metasta tic esophageal squamous cell caricinoma: ERCC1 exression predicts response to chemotherapy[J]. Med Oncol, 2013, 30(1): 343.
[18]樊青霞, 邢国臣, 吴欣爱, 等. 化疗前食管癌组织中ERCClmRNA检测对化疗疗效的预测价值[J]. 郑州大学学报(医学版), 2005, 40(1): 64-67.
[19]李笑秋, 胡冰, 王刚, 等. ERCC1表达水平与晚期食管癌患者含奈达铂方案化疗疗效的相关性[J]. 安徽医科大学学报, 2010, 45(6): 789-791.
[20]Lee S, Park YH, Kim KH, et al. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as perdicitive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma[J]. Br J Cancer, 2010, 103(6): 845-851.
[21]Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histo- pathological response to neoadjuvant radiochemotherapy in esophageal cancer[J]. Clin Cancer Res, 2004, 10(11): 3794-3799.